AKT1 and cancer: Hyperactivation of PI3K/AKT and MAPK signaling caused by EGFR mutations can stimulate proliferation, invasion, and migration abilities of cancer cells20–23, with these effects being suppressed by PI3K and MEK inhibitors24.